NasdaqGS:ALNYBiotechs
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations
Alnylam Pharmaceuticals (ALNY) has come back into focus after the company outlined 2030 financial goals and reiterated AMVUTTRA’s central role, even as fresh headlines highlighted its AI partnership with Inceptive Nucleics.
See our latest analysis for Alnylam Pharmaceuticals.
Despite the recent AI collaboration and refreshed 2030 goals, Alnylam’s share price has been under pressure year to date, with a year to date share price return of down 25.6%. However, the 3 year total shareholder return...